An individual capital investment plan to build new research facilities and equipment at the Kawashima Plant, including a new injectable drug building and the EMITS research building, and to strengthen the research and development infrastructure. It covers projects tied to a specific site and timeframe, commenced in 2021 and completed in 2022.